https://www.goodrx.com/exdensur/what-is
Exdensur (depemokimab): Uses, Side Effects, Dosage & Reviews
Learn about Exdensur (depemokimab) usage and dosing. Read the latest news and reviews about the drug as well as potential side effects and popular alternatives.
side effectsexdensurdepemokimabusesdosage
https://www.gsk.com/en-gb/media/press-releases/exdensur-depemokimab-approved-by-us-fda-for-the-treatment-of-severe-asthma/
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma | GSK
SWIFT data included reduction in exacerbations requiring hospitalisation and/or emergency department visits with depemokimab.
https://www.gsk.com/en-gb/media/press-releases/depemokimab-late-breaking-data-presented-at-ers-show-a-54-reduction-in-severe-asthma-exacerbations/
Depemokimab late-breaking data presented at ERS show a 54% reduction in severe asthma exacerbations...
SWIFT-1 and SWIFT-2 phase III data show depemokimab delivered statistically significant and clinically meaningful reduction in exacerbations
https://exdensur.com/
An SEA Treatment Option | EXDENSUR (depemokimab-ulaa)
Discover EXDENSUR (depemokimab-ulaa), a treatment option for severe asthma with an eosinophilic phenotype. Learn about starting EXDENSUR and available patient...
seatreatmentoptionexdensurdepemokimab
https://clarivate.com/drugs-to-watch/drugs-to-watch-listing/depemokimab/
What is Depemokimab & When will Depemokimab be available?
Discover Depemokimab, a twice-yearly IL-5 biologic delivering sustained control for severe asthma and other inflammatory conditions.
what isdepemokimabavailable
https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-phase-iii-severe-asthma-trials-of-depemokimab/
GSK announces positive results from phase III severe asthma trials of depemokimab | GSK
Primary endpoints met in SWIFT-1 and SWIFT-2 trials with statistically significant reduction in exacerbations over 52 weeks vs. placebo
positive resultsphase iii